SCHEMBL19375954

SCHEMBL19375954

CCCCc1nc(=O)c(C(=O)N2CCC(c3cccnc3)C2)c(O)n1-c1c(OC)cccc1OC

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 20/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19375923 0.92 APLNR (0.80) APLNR
SCHEMBL19404807 0.91 APLNR (0.79) APLNR
SCHEMBL19405085 0.91 APLNR (0.79) APLNR
SCHEMBL19376044 0.89 APLNR (0.67) APLNR
SCHEMBL19376171 0.88 APLNR (0.70) APLNR
SCHEMBL19375858 0.88 APLNR (0.67) APLNR
SCHEMBL19375882 0.88 APLNR (0.80) APLNR
SCHEMBL19376225 0.87 APLNR (0.72) APLNR
SCHEMBL19375989 0.86 APLNR (0.71) APLNR
SCHEMBL19375934 0.86 APLNR (0.71) APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3433247-B1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-09-08 — — EP claimed
CN-109195963-B 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists 百时美施贵宝公司 2021-04-23 — — CN claimed
US-10590113-B2 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-17 — — US claimed
US-10106528-B2 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2018-10-23 — — US claimed
EP-3433247-B1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-09-08 — — EP disclosed
CN-109195963-B 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists 百时美施贵宝公司 2021-04-23 — — CN disclosed
US-10590113-B2 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-17 — — US disclosed
US-20190002441-A1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS BRISTOL MYERS SQUIBB CO (US) 2019-01-03 — — US disclosed
US-10106528-B2 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2018-10-23 — — US disclosed
US-20170275272-A1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2017-09-28 — — US disclosed
US-20170275272-A1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002441-A1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS AP2A1, P2RX5, AP3M1 APLNR 32/4885
US-10106528-B2 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists AP2A1, P2RX5, AP3M1 APLNR 32/4885
US-20170275272-A1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS AP2A1, P2RX5, AP3M1 APLNR 32/4885
US-10590113-B2 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists AP2A1, P2RX5, AP3M1 APLNR 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback